Korro Bio Inc

KRRO has carved a Stage 1 base after a steep capitulation, enabling mean-reversion entries. The medium-term bias is bullish under mean-reversion eligibility and defined support. Recently, price has held a pullback into the rising 9/21/50-day EMA zone and prior consolidation highs, showing no short-term exhaustion. This presents a favorable entry on a supportive interaction. A breakdown below the EMA confluence and base support would invalidate this bullish posture.

• ↑HC Wainwright reiterates Buy rating with $15 price target.
• ↑CoinCodex projects 27.6% upside to $16.46 by end-2026.
• ↓Profitability metrics remain weak, reflecting poor return generation.